Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MDS 2024 | The unmet needs of patients with VEXAS syndrome

Maël Heiblig • 17 Apr 2024
ESH MDS 2024
Myelodysplastic Syndromes VEXAS Syndrome Luspatercept

Maël Heiblig, MD, Hôpital Lyon Sud, Lyon, France, discusses the unmet needs of patients with VEXAS syndrome. To date, no prospective data has been collected, highlighting a need for developing clinical trials to determine effective treatment options for these patients. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Maël Heiblig

5:29
A retrospective study assessing efficacy and safety of ESAs in VEXAS syndrome with or without MDS
Maël Heiblig • 17 Apr 2024
2:11
The current treatment approaches for patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
2:31
What is VEXAS syndrome and what is its association with MDS?
Maël Heiblig • 17 Apr 2024

Related Videos

5:27
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
2:12
AlloSCT for AML with MDS-related features as per the ICC and WHO 2022 classifications
Arnon Nagler • 16 Apr 2024
1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals